DE3131811A1 - Heparin ointment for the percutaneous treatment of thrombophlebitis or varices - Google Patents

Heparin ointment for the percutaneous treatment of thrombophlebitis or varices

Info

Publication number
DE3131811A1
DE3131811A1 DE19813131811 DE3131811A DE3131811A1 DE 3131811 A1 DE3131811 A1 DE 3131811A1 DE 19813131811 DE19813131811 DE 19813131811 DE 3131811 A DE3131811 A DE 3131811A DE 3131811 A1 DE3131811 A1 DE 3131811A1
Authority
DE
Germany
Prior art keywords
ointment
heparin
percutaneous
varices
percutaneous treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19813131811
Other languages
German (de)
Inventor
Michael 4400 Münster Stroetmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STROETMANN M SERAPHARM
Original Assignee
STROETMANN M SERAPHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STROETMANN M SERAPHARM filed Critical STROETMANN M SERAPHARM
Priority to DE19813131811 priority Critical patent/DE3131811A1/en
Publication of DE3131811A1 publication Critical patent/DE3131811A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Heparin ointment is indicated for the percutaneous treatment of thrombophlebitis or varices (state of the therapeutic art). On one such application, about 5% of the heparin employed in the ointment form is transported through the skin and has a therapeutic effect. The transport of the heparin through the skin can be considerably improved in terms of quantity and speed by adding vasoactive substances to the heparin in therapeutically required amounts and distribution ratios.

Description

Heparinsalbe zur percutanen Behandlung von ThrombophlebitidenHeparin ointment for the percutaneous treatment of thrombophlebitis

oder Varizen.or varices.

2. Beschreibung Bei der hiermit anzumeldenden erfindung handelt es sich um eine Heparinsalbe, die hinsichtlich ihrer therapeutischen Wirksamkeit sowie des percutanen Wirkstofftransports - nach Menge und Geschwindigkeit - optimiert ist Es werden niedermolekulare Heparine oder Heparinoide mit natürlich vorkommenden Aminen salzartig gekoppelt Zu den verwendeten Aminen zählen neben Histamin, Ornithin, Arginin Lysin oder deren Polypeptidstrukturen, natürliche Heteropeptide mit gefäßaktivierenden Wirkungen, wie z.B. Bo niedermolekulare Fibrinopeptide, Spermitin oder Putrescin.2. Description The invention to be registered here is is a heparin ointment that is therapeutic in terms of its effectiveness as well of the percutaneous transport of active substances - in terms of quantity and speed - optimized There are low molecular weight heparins or heparinoids with naturally occurring Amines coupled in a salt-like manner In addition to histamine, ornithine, Arginine Lysine or their polypeptide structures, natural heteropeptides with vascular activating Effects such as Bo low molecular weight fibrinopeptides, spermitin or putrescine.

Die eingebrachten Amine dienen u. aO der Ladungsneutralisierung des Heparins. Sie optimieren den percutanen Transport weil sie die Fettlöslichkeit des Produktes steigern. Die eingebrachten Histamine wirken u. a. gefäßaktivierend, was zu einer Erhöhung der Durchblutung im Kapillarbett führt und die Resorption bebeschleunigt.The amines introduced serve, among other things, to neutralize the charge of the Heparins. They optimize the percutaneous transport because they improve the fat solubility of the Increase product. The introduced histamines act among other things. vascular activating what leads to an increase in blood flow in the capillary bed and accelerates resorption.

Claims (1)

3. Ansprüche lOZum Patent angemeldet wird eine Heparinsalbe zur percutanen Behandlung von Thrombophlebitiden und Varizena dadurch gekennzeichnet, daß die Salbe, zur Ereichung eines erwünschten percutanen Wirkstofftransportes, aus speziellen Doppelungen des Heparins zusammengesetzt ist.3. Claims 10 A heparin ointment for percutaneous use is registered for a patent Treatment of thrombophlebitides and varices, characterized in that the ointment, to achieve a desired percutaneous active ingredient transport, from special Duplications of heparin is composed. 2.Zum Patent angemeldet wird eine Heparinsalbe zur percutanen Behandlung nach Anspruch 1, dadurch gekennzeichnet, daß als Grundsubstanz der Salbe eine salzartige Koppelung von Heparinen oder Heparinoiden mit Aminen ( wie z. B. Histamin, Ornithin, Argenin, Lysin, etc. ) verwendet wird.2. A patent application has been filed for a heparin ointment for percutaneous treatment according to claim 1, characterized in that the basic substance of the ointment is a salt-like Coupling of heparins or heparinoids with amines (such as histamine, ornithine, Argenine, lysine, etc.) is used. 3.Zum Patent angemeldet wird eine Heparinsalbe zur percutanen Behandlung nach Anspruch 1, dadurch gekennzeichnet, daß als Grundsubstanz der Salbe eine salzartige Kopplung von Heparinen oder Heparinoiden mit der Polypeptidstruktur von Aminen verwendet wird.3. A patent application has been filed for a heparin ointment for percutaneous treatment according to claim 1, characterized in that the basic substance of the ointment is a salt-like Coupling of heparins or heparinoids with the polypeptide structure of amines is used will. 4.Zum Patent angemeldet wird eine Heparinsalbe zur percutanen Behandlung nach Anspruch 1, dadurch gekennzeichnet, daß als Grundsubstanz der Salbe eine salzartige Koppelung von Heparinen oder Heparinoiden mit natUrlichen Heteropeptiden verwendet wird.4. A patent application has been filed for a heparin ointment for percutaneous treatment according to claim 1, characterized in that the basic substance of the ointment is a salt-like Coupling of heparins or heparinoids with natural heteropeptides is used will. 5.Zum Patent angemeldet wird eine Heparinsalbe zur percutanen Behandlung nach den Ansprüchen 1 bis 4, dadurch gekennzeichwert, daß die Heparinsalbe mit gefäßaktivierenden Substanzen, wie z. B. Histamin und Heteropeptiden ( Fibrinopeptiden, Spermitin, Putrescin, etc. ), versetzt ist.A heparin ointment for percutaneous treatment has been registered for a patent according to claims 1 to 4, characterized in that the heparin ointment with vascular activating Substances such as B. histamine and heteropeptides (fibrinopeptides, spermitin, Putrescine, etc.).
DE19813131811 1981-08-12 1981-08-12 Heparin ointment for the percutaneous treatment of thrombophlebitis or varices Withdrawn DE3131811A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19813131811 DE3131811A1 (en) 1981-08-12 1981-08-12 Heparin ointment for the percutaneous treatment of thrombophlebitis or varices

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813131811 DE3131811A1 (en) 1981-08-12 1981-08-12 Heparin ointment for the percutaneous treatment of thrombophlebitis or varices

Publications (1)

Publication Number Publication Date
DE3131811A1 true DE3131811A1 (en) 1983-04-21

Family

ID=6139127

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19813131811 Withdrawn DE3131811A1 (en) 1981-08-12 1981-08-12 Heparin ointment for the percutaneous treatment of thrombophlebitis or varices

Country Status (1)

Country Link
DE (1) DE3131811A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005646A1 (en) * 1987-12-21 1989-06-29 Bukh Meditec A/S Uses of sulphated sugars
US5908836A (en) * 1987-12-21 1999-06-01 Bar-Shalom; Daniel Protecting skin from radiation damage using sulphated sugars

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005646A1 (en) * 1987-12-21 1989-06-29 Bukh Meditec A/S Uses of sulphated sugars
US5908836A (en) * 1987-12-21 1999-06-01 Bar-Shalom; Daniel Protecting skin from radiation damage using sulphated sugars
US5916880A (en) * 1987-12-21 1999-06-29 Bukh Meditec A/S Reduction of skin wrinkling using sulphated sugars

Similar Documents

Publication Publication Date Title
EP0176033A3 (en) Isoxazolecarboxylic-acid derivatives, their preparation and use
ATE105482T1 (en) TREATMENT OF CANCER WITH SOMATOSTATIN AND ANALOGS THEREOF.
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
DE91543T1 (en) ANTI-INTERFERON ANTIBODIES AND METHOD FOR THE PRODUCTION THEREOF.
BG60261B2 (en) Lon-acting formulation of cefaclor
IL58697A0 (en) Analgesic pharmaceutical compositions in the form of effervescent powders comprising metoclopramide
CH640138A5 (en) PHARMACEUTICAL PREPARATION FOR INACTIVATING VIRUSES.
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
Houck et al. THE EFFECT OF SODIUM DILANTIN ADMINISTRATION UPON THE CHEMISTY OF THE SKIN
DE3131811A1 (en) Heparin ointment for the percutaneous treatment of thrombophlebitis or varices
US4186196A (en) Topical anti-fungicide preparation
Freydberg-Lucas et al. Der Calciumstoffwechsel verschiedener Organe bei jungen und alten Tieren
DE2428955A1 (en) PROCESS FOR EXTRACTION OF COMPONENTS WITH ANTICOAGULATING EFFECT IN VIVO FROM SNAKE POISON AND PRODUCTS OBTAINED FROM IT
DE2152112A1 (en) Anti-tumor and vaccine preparations
Jin et al. The Quaternary mammalian faunas from Qingshantou site, Jilin province.
JPS5585526A (en) Remedy for allergic disease
EP0377413B1 (en) Pharmaceutical compositions having topical use comprising ticlopidine
DE2819131C2 (en)
Stoll et al. Die pH-Abhängigkeit der Wirkung einiger Antibiotika im Plattentest
DE1802386C2 (en) Process for the production of cytobiotic globulins
DD235418A1 (en) METHOD FOR OBTAINING CANCER-INHIBITING MISTELEXTRACTS WITH DEFINED LACTINE CONTENT
Urbasch Antagonistische Wirkung von Trichothecium roseum (Pers.) Link ex Gray auf Pestalotia funerea Desm.
DE942534C (en) Process for the production of durable and highly effective solutions or suspensions of antibiotic agents
Rose et al. The effect of tartrate upon the calcium oxalate precipitated from whole urine after rapid evaporation
DE3805523A1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TRANSDERMAL APPLICATION OF HEPARIN

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8130 Withdrawal